All In Biotech

Drug Trial Radar · NCT04922957

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

12

Actual

Start

Sep 1, 2021

Primary completion

Apr 1, 2022

Study completion Mar 11, 2024

Sponsor

Lead sponsor
Enlivex Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Jun 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10\^9 cells vs placebo (1:1) in adult hospitalized patients with severe or critical Coronavirus Disease 2019 (COVID-19) with associated acute respiratory distress syndrome (ARDS). Patients will be followed for efficacy and safety for 6 months. The trial will include periodic and ad-hoc DSMB review during the study period.

Conditions

  • Covid19

Interventions

  • ALLOCETRA-OTSDrug

    The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.

  • PlaceboOther

    Ringer's lactate solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time (days) to improvementTime frame: 28 days
  2. Support by IMV/ECMOTime frame: 28 days
  3. MortalityTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Ein Kerem Medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.